Company intelligence / Profile preview

Selecxine

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Selecxine's lead asset SLC-3010 received IND clearance from MFDS for Phase 1/2 clinical trials in December 2022. SLC-3010 is a non-covalent conjugate of IL-2 and anti-hIL-2 antibody (TCB2) designed to preferentially stimulate immune cells related to anti-cancer activities rather than immune suppression[1][4].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesImmunotherapeutics
Industry: Biotech

Drug pipeline

3 assets

SLC-3010

2 more assets in the full pipeline.

Request access →

Partnerships

GenScript ProBio

Beyond the preview

Go deeper on Selecxine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selecxine.

Explore the full profile